Genitourinary malignancies in kidney transplant recipients

Int J Urol. 2024 Dec;31(12):1321-1329. doi: 10.1111/iju.15588. Epub 2024 Sep 24.

Abstract

Advances in immunosuppressive therapy and postoperative management have greatly improved the graft and patient survival rates after kidney transplantation; however, the incidence of post-transplant malignant tumors is increasing. Post-renal transplantation malignant tumors are associated with renal failure, immunosuppression, and viral infections. Moreover, the risk of developing cancer is higher in kidney transplant recipients than in the general population, and the tendency to develop cancer is affected by the background and environment of each patient. Recently, cancer after kidney transplantation has become the leading cause of death in Japan. Owing to the aggressive nature and poor prognosis of genitourinary malignancies, it is crucial to understand their epidemiology, risk factors, and best practices in kidney transplant recipients. This review has a special emphasis on the epidemiology, risk factors, and treatment protocols of genitourinary malignancies in kidney transplant recipients to enhance our understanding of the appropriate management strategies. Optimal immunosuppressive therapy and cancer management for these patients remain controversial, but adherence to the general guidelines is recommended.

Keywords: genitourinary malignancy; immunosuppression; kidney transplantation.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunosuppression Therapy / adverse effects
  • Immunosuppressive Agents* / adverse effects
  • Immunosuppressive Agents* / therapeutic use
  • Incidence
  • Japan / epidemiology
  • Kidney Transplantation* / adverse effects
  • Postoperative Complications* / epidemiology
  • Postoperative Complications* / etiology
  • Postoperative Complications* / therapy
  • Risk Factors
  • Transplant Recipients / statistics & numerical data
  • Urogenital Neoplasms* / epidemiology
  • Urogenital Neoplasms* / etiology
  • Urogenital Neoplasms* / therapy

Substances

  • Immunosuppressive Agents